Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases

A compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• one of R1 and R2 is Ra, and the other is hydrogen or Ra;
• or R1 and R2 together with the carbon atom to which they are attached form a blocking group which functions to prevent metabolic reaction at the 3-position;
• wherein said blocking group is C3-8 cycloalkyl group substituted with 1, 2, 3, 4 or 5 Rb;
• a C2-6 alkenyl group substituted with 1, 2, 3, 4 or 5 Rb;
• or an optionally substituted heterocyclic group;
• R5, R6, R7 and R8 are each independently selected from hydrogen, Rf and Rg;
• R9 is hydrogen, C1-6 alkyl or a Group I metal ion;
• Ra is selected from —C(O)Rc, —C(O)ORc, —OC(O)Rc, —N(Rc)Rd, —C(O)N(Rc)Rd, —N(Rc)C(O)Rd, C1-6 alkyl substituted with 1, 2, 3, 4 or 5 Rb;
• C2-6 alkenyl substituted with 1, 2, 3, 4 or 5 Rb;
• carbocyclyl substituted with 1, 2, 3, 4 or 5 Rb;
• and optionally substituted heterocyclyl;
• Rb is selected from —N(Rc)Rd, —C(O)N(Rc)Rd, carbocyclyl and heterocyclyl, wherein the carbocyclyl and heterocyclyl groups are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halo, cyano, amino, hydroxy, nitro, C1-6 alkyl and C1-6 alkoxy;
• Rc and Rd are each independently hydrogen or Re;
• Re is selected from C1-6 alkyl and C2-6 alkenyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halo, cyano, amino, hydroxy, nitro, C1-6 alkyl and C1-6 alkoxy;
• Rf is selected from C1-6 alkyl and C2-6 alkenyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 Rg;
• Rg is selected from halo, trifluoromethyl, cyano, nitro, —ORc, —C(O)Rc, —C(O)ORc, —OC(O)Rc, —S(O)1Rc, —N(Rc)Rd, —C(O)N(Rc)Rd, —N(Rc)C(O)Rd, —S(O)1N(Rc)Rd and —N(Rc)S(O)1Rd;
• 1 is 0, 1 or 2.